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Most transcription factors, including nuclear receptors, are widely modeled as binding regulatory elements as monomers,
homodimers, or heterodimers. Recent findings in live cells show that the glucocorticoid receptor NR3C1 (also known as
GR) forms tetramers on enhancers, owing to an allosteric alteration induced by DNA binding, and suggest that higher olig-
omerization states are important for the gene regulatory responses of GR. By using a variant (GRtetra) that mimics this al-
losteric transition, we performed genome-wide studies using a GR knockout cell line with reintroduced wild-type GR or
reintroduced GRtetra. GRtetra acts as a super receptor by binding to response elements not accessible to the wild-type re-
ceptor and both induces and represses more genes than GRwt. These results argue that DNA binding induces a structural
transition to the tetrameric state, forming a transient higher-order structure that drives both the activating and repressive
actions of glucocorticoids.
[Supplemental material is available for this article.]
Themultimeric structure adopted by transcription factor complex-
es at their genomic sites of interaction is a longstanding problem in
transcription biology. Information bearing on this question is
often inferred from indirect data sources. Many transcription fac-
tors, including nuclear receptors, are found in crystal structures
as either homodimers or heterodimers. These structures in turn
suggest preliminary models for how the proteins might interact
with regulatory sites in the genome. Genomic methods, such
as digital genomic footprinting (DGF) (Hesselberth et al. 2009)
or chromatin immunoprecipitation (ChIP)-exo (Rhee and Pugh
2011), extend these models based on the thesis that the “foot-
print” left on the DNA (either DNA protection for DGF, or protein
complex boundaries in the case of ChIP-exo) is informative as to
the structure of the bound complex. From a rigorous viewpoint,
these staticmethods address the nature of the DNA interaction do-
mains, not necessarily the actual status of the full protein complex.
Finally, many studies invoke the presence or absence of a DNA
motif for a given factor (or binding partner) in a ChIP coupled
with deep sequencing (ChIP-seq) peak as evidence for the compo-
sition of the complex.
In contrast, methods that measure directly the size of a com-
plex in live cells can address the actual multimeric status of a given
complex in real time. The bound TP53 protein (also known as p53)
has been described as a tetramer, based on both static methods
(Emamzadah et al. 2011; Rhee and Pugh 2011) and live cell
approaches (Gaglia et al. 2013). More recently, the DNA-bound
STAT3 factor was also confirmed to be a tetramer, based on pair
correlation of molecular brightness (pCOMB), another live cell
technique (Hinde et al. 2016). These findings illustrate the inade-
quacy of static cell data sets for an accurate and complete under-
standing of molecular status for regulatory complexes.
When the glucocorticoid receptor response element (GRE)
was elucidated in the 1980s (Huang et al. 1981), it was postulated
that the receptor likely binds DNA as a dimer owing to the palin-
dromic nature of the GRE consensus motif (Evans 1988). The fur-
ther characterization of the crystal structure of the DNA-binding
domain (DBD) fragment appeared to confirm this theory (Luisi
et al. 1991). This line of research continued in the 1990s using
the A465T mutation within DBDs of the mouse glucocorticoid re-
ceptor NR3C1 (also known as GR), known as the GRdim mutant
(Hecket al. 1994; Reichardt et al. 1998), and led to thedevelopment
of the dissociated model of glucocorticoid action (Clark and Belvisi
2012). This model describes two modes of GR binding that direct
distinct transcriptional responses, direct dimericbinding for induc-
tion or tethered monomeric binding for repression, and theoreti-
cally allow the development of selective glucocorticoids that
favor one form of receptor binding, thus eliciting therapeutically
favorable repressive responses. Further mechanisms for GR action
have proliferated in recent years, including composite GREs, nega-
tiveGREs, competitiveGREs, squelching, etc.,models that propose
a variety of bindingmodes (Ratman et al. 2013). These concepts are
invariably based on static, population-basedmethods, aswell as in-
ferential approaches derived frommotif profiling.
We recently examined GR’s oligomeric state at response
elements in live cells, using an advanced fluorescence micro-
scopy technique termed Number and Brightness (Digman et al.
2008). We reported that receptor binding on an activating
GRE induces tetrameric quaternary structures, suggesting that tet-
ramers are the final active formofGR (Presman et al. 2016). Among
the nuclear receptor family, only the retinoid X receptor (RXR)
has been postulated to exist as a full-length tetrameric complex
(Kersten et al. 1995). This state of the RXR has generally been con-
sidered a repressive or inactive form, with ligand-induced dis-
ruption to activating dimers. However, one case has been
reported in which the RXR tetramer was invoked as an activator
(Mangelsdorf et al. 1991).
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Tounveil the relationship betweenGR’s oligomerization state
and transcriptional outcome, we have examined chromatin bind-
ing and receptor-dependent gene regulation for the receptor in
two GR null cell systems. A null mouse embryonic fibroblast
(MEF) system was described previously (Presman et al. 2014). A
second GR knockout (GRKO) was established by eliminating all
endogenous copies of the receptor gene in the 3617 mouse mam-
mary cell line (Voss et al. 2011).We used these systems in conjunc-
tion with a mutation in the GR DBD (P481R) that mimics a GR
structural transition induced by DNA binding (van Tilborg et al.
2000).We showed previously (Presman et al. 2016) that this muta-
tion (referred to herein as GRtetra) induces a constitutive tetramer-
ic state for all activated receptors in the nucleus.
Results
Generation of a GRKO/GR tetrameric cell system
Our group has developed numerous cell lines from murine C127
mammary adenocarcinoma cells to study GR action (McNally
et al. 2000). By using CRISPR/Cas9, we first knocked-out the stably
integrated rat GFP-GR gene in the 3617-cell model. We used this
parental cell line for making a GRKO system in which we could re-
introduce a wild type or a forced tetrameric GR mutant (GRtetra;
more details later), both GFP-tagged, to study receptor binding
and gene response (for details, see Methods) (Supplemental Fig.
S1A). Western blots show no detectable GR levels in the knockout
cell line (GRKO) (Supplemental Fig. S1B).We confirmed the lack of
hormone response in the GRKO cells via RNA-seq, comparing the
GRKO and parental lines before and after 2 h of 100 nM dexame-
thasone (Dex) (Supplemental Fig. S1C; Supplemental Table S1).
ChIP-seq, with either anti-GR or anti-GFP antibodies, confirms
the lack of GR binding in the GRKO line compared with the other
cell lines with reintroduced GR (Supplemental Fig. S1D,E). As
shown in the GRwt cell line, there is a good correlation in binding
between the two antibodies (Supplemental Fig. S1F). We used the
anti-GFP antibody herein because of a better signal-to-noise ratio
compared with anti-GR (Supplemental Fig. S1G).
Tetrameric GR mutant occupies more genomic sites than GRwt
and efficiently increases chromatin accessibility
Although it is widely accepted GR’s transcriptional output
depends heavily on its dimeric/monomeric status (Vandewalle
et al. 2018), recent live-cell imaging evidence suggests that GR
forms higher oligomerization states, most likely a tetramer, after
engaging with chromatin in vivo (for a summary, see Supple-
mental Fig. S1A; Presman andHager 2017).We reasoned that shift-
ing the equilibrium of the receptor toward tetramers should affect
its ability to bind to chromatin. To test this hypothesis, we per-
formed ChIP-seq in the presence or absence of Dex (1 h, 100
nM) in our engineered cells expressing GRwt, or the GR-P481R
(GRtetra) receptor (cell line characterization in Supplemental
Figs. S1B, S2A–F). This point mutation mimics the DNA-bound
conformation of the receptor (van Tilborg et al. 2000), likely
changing the conformation of GR to constitutively expose tran-
scriptional activation surfaces normally available only when
bound to DNA. More recently, we have shown liganded GRtetra
forms tetramers throughout the nucleus in live cells (Presman
et al. 2016).Western blots from crosslinked and sonicatedmaterial
did not show any evidence of potential differences in detectability
or stability between GRwt and GRtetra under the ChIP protocol
(Supplemental Fig S2B).
By using a relatively stringent peak calling protocol (see
Supplemental Methods), we obtained 5923 binding sites for
GFP-GRwt (cluster [C] 1) using an anti-GFP antibody, 2124 bind-
ing sites (C2) using anti-GR, and 11,003 sites for GFP-GRtetra
(C3) using anti-GFP (Supplemental Fig. S1D,E,G). For a guide to
all clusters described in this work, please refer to Supplemental
Figure S2G. ChIP peaks were aligned on their GR peak summits
and sorted to obtain a heat map with the most highly occupied
sites at the top of each cluster (Fig. 1A). Binding profile compari-
sons between reintroduced GFP-GRwt, GFP-GRtetra, and endoge-
nous GR in 3134 cells (John et al. 2011) reveal three distinct
binding clusters (clusters C4–C6) (Fig. 1A). GRtetra binding spans
all three clusters, whereas GRwt significantly occupies only C4
(Supplemental Fig. S3A,B). This clearly indicates that the mutant
binds to more sites than GRwt. Also, signal intensity suggests
GRtetra binds more strongly than GRwt (Supplemental Fig. S3A).
The C5 represents sites that are not significantly occupied by
the stably integrated GFP-GRwt; however, these enhancers re-
mained engaged by the endogenous GR in 3134 cells (Fig. 1A;
Supplemental Fig. S3C). One possibility is that the GFP-tag on
the reintroduced receptors may inhibit binding compared with
the endogenous GR. Another possibility is that during the GRKO
generation, the chromatin landscape partially changed, and
some of the GR sites that require other initiators are no longer
accessible. Nevertheless, GFP-tagged GRtetra overcomes this nega-
tive effect and binds to additional sites (C6) that even endogenous
GR cannot bind (Fig. 1A; Supplemental Fig. S3A–C). Representa-
tive Genome Browser track examples are shown in Supplemental
Figure S3D,F.
The vast majority (>90%) of GR binding sites occur within
distal intergenic and intronic genomic regions (Supplemental
Fig. S4A), consistent with previous reports on GR genomic distri-
bution (So et al. 2007). Hence, GRtetra enriches at similar genomic
loci as GRwt. De novomotif analyses of GRtetra binding sites show
that the C4–C6 sites contain GREs (Fig. 1B; Supplemental Table
S2), with highest frequency at the GRtetra-specific C6 and lowest
at C4 sites shared with GRwt. There is <1% enrichment of half
GREs at C6, indicating that GR tetramerization drives the receptor
binding to full GREs. Consistent with the important role the AP-1
complex (JUN-FOS) has onGRbinding in this cell line (Biddie et al.
2011), de novomotif analyses shows enrichment of the JUN (AP-1)
motif at all clusters with varying degree (Fig. 1B). Although C4
sites shows JUN binding (Fig. 1A), frequently have the AP-1 motif
(Fig. 1B), and are close to an AP-1 peak in 3134 cells (median
130 bp) (Fig. 1C), there is no JUN binding at C6 sites, and the me-
dian distance between the GR peak and JUN peak is 10 kb. This
analysis suggests that GRtetra is less dependent on AP-1, resem-
bling a “pioneer-like” factor.
The mouse genome harbors millions of putative GREs;
however, GR binds only a small subset of them in a highly tis-
sue-specific manner. Chromatin landscape appears to be a major
determinant in defining GR access to its response elements (Voss
and Hager 2014). The majority of cell-specific GR-enhancers ap-
pear to be primed or “preprogramed” for GR binding, as measured
by DNase I hypersensitivity assays. Another subset of enhancers
is initially closed and actively opened by GR (i.e., de novo sites),
showing context-dependent pioneer activity of this receptor
(John et al. 2011; Johnson et al. 2018). To assess the chromatin
environment of GRtetra binding sites, we measured (1) chromatin
accessibility by the assay for transposase-accessible chro-
matin (ATAC)-seq and (2) the binding profile of the chromatin
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cofactor (John et al. 2011). In both cases, the data were sorted in
the same order as the GR ChIP data. In all clusters, GRtetra more
effectively increases chromatin accessibility and SMARCA4 recruit-
ment after Dex treatment, especially in C5 and C6 (Fig. 1A;
Supplemental Fig. S4B,C). The SMARCA4 ChIP-seq and ATAC-
seq data parallel the SMARCA4 ChIP-seq and DNase-seq data
from the 3134 cells (Fig. 1A; Supplemental Fig. S3C), except in
the additional GRtetra-specific sites (C6). There is no binding
of GR, SMARCA4, JUN, or EP300 (also known as p300) at C6
sites in the presence or absence of hormone in 3134 cells (Fig.
1A; Supplemental Fig. S3C), and these sites are not accessible be-
fore hormone in GRtetra-expressing cells (Fig. 1A; Supplemental
Fig. S4B). Furthermore, nucleosome mapping in the 3134 cell
line by MNase-seq (Johnson et al. 2018) shows high nucleo-
some presence around C6 sites before hormone (Fig. 1A;
Supplemental Fig. S3C). On the other hand, C4 are mainly—but
not completely—depleted of nucleosomes as resorting C4 sites
based on nucleosome occupancy reveals that GRwt can also pene-
trate closed, nucleosomal chromatin (Supplemental Fig. S4D).
Taken together, we conclude that GRtetra functions as amore
effective pioneer factor than GRwt. Forcing the receptor into a tet-
rameric conformation appears to drive the protein into an optimal
conformation. Not only does GRtetra bind better to sites already
accessible to GRwt, but also it penetrates and recruits SMARCA4
to sites that are SMARCA4 free, AP-1 free, nucleosomal, not acces-
sible to nucleases (ATAC-seq), and enriched for GRE motifs.
Figure 1. Chromatin analysis of tetrameric GR mutant. (A) Comparison of GRwt and GRtetra binding reveals three clusters, C4–C6: C4, shared by GRwt
and GRtetra; C5, shared by endogenous GR in 3134 cells and GRtetra; C6, GRtetra-specific sites. Heat maps represent ChIP-seq, ATAC-seq, andMNase-seq
data as indicated. Each heat map represents ± 1 kb around the center of the GR peak. Binding intensity scale is noted below on a linear scale. Heat maps are
sorted based in GRtetra binding intensity. All heat maps are normalized to a total of 10 million reads and further to local tag density. (B) De novo motif
analysis. The percentage of sites with a motif, P-value of enrichment, and position-weight matrix (PWM) are shown. A full list of enriched de novo motifs
is shown in Supplemental Table S2. (C ) Cumulative distribution function (CDF) between C4–C6 binding sites and JUN (AP-1) peak in 3134 cells. Each clus-
ter is color-coded with median distance shown for each cluster. Gray dashed line depicts median.
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An obligate tetrameric GR induces and represses more genes than
the wild-type receptor
To determine if more efficient binding of GRtetra influences Dex-
regulated gene expression, we performed RNA-seq in each cell line
(GRwt, GRtetra) as done with the GRKO and parental cells
(Supplemental Table S1).We included only genes that are annotat-
ed in the RefSeq database and eliminated any genes with duplicate
gene symbols that may be indicative of alternative TSS or similar
variants. Since we sequenced GRwt and GRtetra cell lines
Figure 2. Gene expression analysis of tetrameric GRmutant. (A,B) Venn diagrams of up-regulated or down-regulated genes from RNA-seq data after 2-h
Dex treatment. (C,D) Box plots represent the log2 fold change of the 109 (up-regulated) or 18 (down-regulated) GRwt and GRtetra shared genes.
(E) Examples of Dex-regulated genes from each subset. Data shown as fold change of RNA-seq RPKM values for GRKO, GRwt, and GRtetra cells. For
each cell line, the nontreated sample was used as reference point. (F,G) C4–C6 sites were associated to the nearest Dex up-regulated gene (F) or Dex
down-regulated gene (G) based on linear proximity. Box plots represent log2 fold change (Dex/NT) of the Dex-regulated gene in GRwt- and GRtetra-ex-
pressing cells that are associated with GR binding sites in C4 (left), C5 (middle), or C6 (right). All box plot comparisons are normalized to total of 10 million
reads. (H,I) Shared and GRtetra uniquely Dex up-regulated (H) or Dex down-regulated (I) genes were associated to the closest GR binding site in one of the
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independently, technical variability in library preparation and/or
sequencing runs do not allow us to directly compare baseline ex-
pression levels between cell lines; however, other no-treatment
RNA replicates, prepared and sequenced at the same time, do
show basal expression similarity between GRwt and GRtetra cell
lines (Supplemental Fig. S4E,F and Supplemental Methods).
Moreover, results show that hormone treatment both induces
(Fig. 2A) and represses (Fig. 2B) more target genes in GRtetra cells
compared to GRwt expressing cells (Supplemental Table S1).
Although the shared Dex up-regulated genes between GRwt and
GRtetra are similarly induced (Fig. 2C), common Dex-repressed
genes are done so to a much greater extent in the GRtetra cells
(Fig. 2D). The much stronger repressive effect of GRtetra contrasts
with the model that GR-mediated transcriptional repression acts
through monomeric modes of receptor interaction with chroma-
tin (Lim et al. 2015). Representative examples of each category
are shown as bar graphs (Fig. 2E).
We next analyzed the correlation between (1) the closest Dex-
regulated genes to receptor binding sites for each cluster in GRwt
orGRtetra cells (peak-centric analysis) (Fig. 2F,G) and (2) the clusters
with closest GR binding sites to a regulated gene (gene-centric
analysis) (Fig. 2H,I); for details, see Supplemental Methods.
Within the C4 cluster, although up-regulation of genes does not
differ between the GRtetra- and GRwt-expressing cells (Fig. 2F),
GRtetra appears to down-regulate genes more effectively (Fig.
2G). In contrast, within the C5 cluster, GRtetra both up- and
down-regulates genes better. The GRtetra-exclusive cluster C6
is also close to many Dex up-regulated genes that are uniquely
expressed in GRtetra cells (Fig. 2F). Representative examples are
shown as Genome Browser tracks for C4 sites and C6 sites
(Supplemental Fig. S5A–D). From the gene-centric perspective, look-
ing at up-regulated genes only, even though C4 peaks associate
more frequently with target genes, C5 and C6 are significantly
more associated to tetra-unique-regulated genes than to shared-
regulated genes (Fig. 2H). Conversely, the association significantly
decreases for C4 sites. These differences are not observed with
down-regulated genes (Fig. 2I). Moreover, C4 sites are closest
to the regulated gene TSS, whereas C6 are the furthest away
(Supplemental Fig. S5E–H). Thus, C6 sites do not cluster “near” tet-
ra uniquely regulated genes, suggesting that GRtetra sites may be
part of chromatin loops to regulate these genes. Indeed, it has
been shown stimulus-dependent biological processes are more
likely to interact with distal rather than proximal binding sites
(Heidari et al. 2014). Taken together, this strongly suggests the
ability of GRtetra to bind to new genomic sites leads to trans-
criptional regulation of additional target genes. Of note, the
GRtetra C6 unique sites areweakly associatedwith down-regulated
genes (Fig. 2G), consistent with a previous report claiming many
glucocorticoid down-regulated genes lack nearby GR binding sites
(Reddy et al. 2009). It is also plausible that newly generatedGRtetra
sites influence more gene induction than repression through
penetration of closed chromatin sites.
In conclusion,GRtetra is less dependent on JUN, and its high-
er oligomerization state generates a “super receptor” that can enga-
ge in novel GREs unavailable to wild-type receptors. GRtetra has
increased transcriptional effects, especially in hormone-repressed
genes, and can more effectively act as a pioneer factor than GRwt.
New tetrameric GR binding sites are marked with H3K4me1
To investigate if particular histone marks enable GRtetra to target
only a certain subset of GREs, we measured enhancer activation
status by ChIP-seq of histone 3 lysine 27 acetylation (H3K27ac)
and histone 3 lysine 4 monomethylation (H3K4me1). These two-
histone modifications can be used to map active and poised
enhancers, respectively (Creyghton et al. 2010). Comparing
H3K27ac and H3K4me1 levels in GRtetra cells and GRwt cells
shows that practically all GR binding sites shared by both cell lines
(C4) have the classical bimodal distribution of H3K27ac after
Dex treatment, which is only observed in a subset of sites in the
nontreated conditions (Fig. 3A,B). Resorting the C4 cluster based
on chromatin preaccessibility revealed that the subset that displays
a bimodal distribution of H3K27ac and H3K4me1 before hormone
treatment is largely the preaccessible sites (top 25% Supplemental
Fig. S6A,B). C4 sites with low or absent preaccessibility, de novo
sites, are marked with H3K4me1 before hormone exposure, indi-
cating that GR binding activates these poised enhancers (bottom
25%) (Supplemental Fig. S6A,B). In comparison, the Dex-induced
bimodal H3K27ac distribution in C5–C6 sites is only observed in
GRtetra cells (Fig. 3A,B), which also correlates with SMARCA4 re-
cruitment (Fig. 1A). These observations strongly suggest that these
enhancers are activated by GRtetra. In addition, if we split the C4
peaks according to their associationwith their closest up- or down-
regulated genes as in Figure 2, F and G, a clear opposite pattern
emerges, wherein H3K27ac increases with up-regulation and de-
creases with down-regulated associated genes (Supplemental Fig.
S6C). The correlation between down-regulation and decreased
H3K27ac acetylation is consistent with a direct repressive activity
of both GRwt and GRtetra. Nevertheless, the C5–C6 peaks corre-
lates well only with up-regulation of GRtetra-dependent genes,
suggesting GRtetra repressive action may involve indirect or even
direct long-distance action.
H3K4me1 was prominently enriched at the center of C5–C6
sites, marking the regions prior hormone exposure (Fig. 3A,B).
There was little change to H3K4me1 after Dex treatment in
the GRwt cells; however, the mark was decreased in GRtetra-
expressing cells. Thus, the histonemarks data agreewith the recep-
tor binding data inwhichC5–C6 sites are activated only inGRtetra
cells. The H3K27ac is enriched at the center of C6 sites before
hormone exposure (Fig. 3A,B); however, a similar presence is ob-
served in the input sample (Supplemental Fig. S7A), suggesting
that it is owing to higher nucleosome occupancy rather than
more of the histone modification. Indeed, both C5 and C6 sites
contain nucleosomes in 3134 cells before hormone treatment,
mirroring the H3K4me1 data (Supplemental Fig. S3C, MNase).
H3K4me1 is enriched significantly more than the input sample
at the C6 sites (Supplemental Fig. S7B), suggesting that GRtetra
can bind H3K4me1-marked binding sites.
To assess the role of H3K4me1 marking GRtetra-specific
sites more closely, we compared H3K4me1 levels at other GR
andGRE-containing binding sites. For this purpose, we download-
ed all the available mouse GR ChIP-seq data sets fromdifferent cell
types from the NCBI Gene Expression Omnibus (GEO). To call
peaks from each data set, we used either available nontreated sam-
ple or input sample from the same data set or from the same labo-
ratory (for details, see SupplementalMethods; Supplemental Table
S3). We compared each data set to GRtetra binding data to differ-
entiate GR peaks from each cell type that are not present in the
GRtetra-expressing cells. We further filtered the GR peaks to only
contain peaks that harbor GRE sequences. In addition, we created
a control GRE data set consisting of 10 iterations of 1000 random
GREs. All the data sets harbor GREs at the center of the site
(Supplemental Fig. S7C). None of the GR binding sites in other
cell types display enrichment of H3K4me1 in the GRtetra-
GR quaternary structure drives chromatin occupancy
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expressing cells (Fig. 3C), including the random GREs
(Supplemental Fig. S7B). This suggests that GRtetra is not targeted
to random GR binding sites occupied in other cell types but to
H3K4me1-marked sites.
Tetrameric GR mutant transcends tissue-specific barriers
As stated above, GR binding is highly tissue specific, with little
overlapping between cell types (Grbesa and Hakim 2017). We
hypothesize that GRtetra new sites might be normally occupied
by GR in other cell tissues; thus, we used previously published
mouse GR ChIP-seq data sets from different cell types to assess
the overlap between the newGRtetra binding sites and these other
GR data sets (see Supplemental Methods). The heat map in Figure
4A was sorted based on the tag density of the other cell line data
with GRtetra-absent sites on the top part and GRtetra binding
sites on the bottom part of the heat map (Supplemental Fig.
S7D, cartoon guide). Different degrees of overlap can be observed
at the GRtetra binding sites between different GR data sets (Fig.
4A, bottom part of the heat map). Of the GRtetra unique sites
(C6), 66% (1198/1808 sites) overlap in at least one of the seven
GR ChIP-seq cell line data sets (Fig. 4B), with GREs being the
Figure 3. Active and poised enhancer marks at GRtetra binding sites. (A) ChIP-seq data of H3K27ac and H3K4me1 at clusters C4–C6. GR binding is
represented as in Figure 1A. A two-color binding intensity scale is used for the histone modification data on a linear scale. (B) Aggregate plots represent
histone modification changes for each cluster; color indicates treatment and GR type. (C) Aggregate plots show the comparison of GRtetra H3K4me1 en-
richment in untreated cells at C6 sites to GR binding sites present in other cell lines not shared with GRtetra cells. AtT-20 (pituitary), mouse embryonic
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Figure 4. GRtetra unique binding sites are occupied by the receptor in other cell types. (A) Heat map comparison of all GRtetra binding sites (1) to en-
dogenous GR binding sites in other cell types (2–10). Data set information shown on the top of the heatmaps. Each cell typewas separated into its ownheat
map. Top heatmaps show cell-type–specific binding sites not occupied by GRtetra. The peak number is shown on the left. Lower heatmaps show all GRtetra
binding sites and the overlap with other cell types. The peak number overlapping between the GRtetra (C4–C6 sites) and the other cell type is shown on the
right of the lower heat map. The number of peaks shared between C6 (GRtetra specific) and the other cell type is indicated with an arrow on the bottom of
the heat map. Heat maps are sorted by GR ChIP-seq binding intensity in the other cell line. (B) Pie chart showing C6 sites unique or shared with at least one
published GR ChIP-seq data set. De novo motif analysis of the most enriched motif shown on the right. Full list of enriched de novo motifs is shown in
Supplemental Table S2. (C,D) Heat map (C) and (D) aggregate plots of C6 sites compared with published mouse liver GR data set reveal two clusters,
C7 (common to both GRtetra unique sites [C6] and GR binding sites in liver) and C8 (unique GRtetra sites not shared with GR data in liver).
(E) De novo motif analysis of C7 sites. Full list of enriched de novo motifs is shown in Supplemental Table S2.
GR quaternary structure drives chromatin occupancy
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most significant motif (Supplemental Fig. S8A–G). As an example,
32% (584/1808) of GRtetra unique sites overlapped with GR data
in the liver (C7) (Fig. 4C,D), with GRE being the most common
motif (Fig. 4E). In addition to GREs, the thyroid hormone receptor
beta (THRB) motif was also present at the shared C7 sites. Because
THRB is an important transcription factor in the liver (Goldstein
and Hager 2015), it suggests the GR sites where GRtetra binds
can be functionally relevant.
The remaining (34%) C6 sites do not overlap with the pub-
lished GR ChIP-seq data sets we analyzed (Fig. 4B). However, the
GREmotif is themost frequently occurringmotif, suggesting these
sites could also be occupied by GR in other, nonsequenced tissues.
Altogether, we conclude GRtetra can penetrate cell-type–specific
barriers to wild-type receptor binding.
The properties of tetrameric GR mutant are retained
in another cell type
To evaluate the generality of our GRtetra results, we compared
receptor binding in wild-type immortalized MEFs as well as GFP-
GRwt or GFP-GRtetra expressed in GRKO MEF (MEF-GRKO)
cells (Presman et al. 2014, 2016). Comparison of the three GRs
in MEFs also shows that GRtetra binds to more sites more strongly
and more significantly than does endogenous GR or GFP-GRwt
(Fig. 5A,B; Supplemental Fig S9A). All MEFwt andMEF-GRwt bind-
ing sites are occupied byMEF-GRtetra (C9); however, MEF-GRtetra
binds to even more sites (C10). Representative Genome Browser
track examples are shown in Supplemental Figure S9, B and C. In
agreement with the adenocarcinoma cells, C10 (GRtetra-exclu-
sive) sites contain higher enrichment of GREs compared with
shared C9 (Fig. 5C; Supplemental Table S2). In addition, ATAC-
seq data and H3K4me1 ChIP-seq from MEFs (Chronis et al.
2017) indicated that C10 sites are less accessible than C9 sites
before hormone exposure, and H3K4me1 marks more clearly the
center of the C10 sites than the C9 sites (Fig. 5A,D,E). Thus,
GRtetra can also target closed chromatin sites in MEFs. Finally,
we compared C10 and H3K4me1 MEF data to GR binding sites
in other cell types (Fig. 5F; Supplemental Fig. S9D,F). The majority
(60%) of theC10 sites are present in at least one of theGRChIP-seq
data sets, with GREs being the most significantly enriched motif
(Fig. 5F; Supplemental Fig. S10). None of the GR binding sites in
other cell types display high levels of H3K4me1 in the MEF-
GRtetra–expressing cells (Supplemental Fig. S9D,E). Thus, all the
properties of GRtetra—pioneer factor-like action, targeted to
H3K4me1-marked GRE sites, and penetrating the cell-type–specif-
ic barrier—are retained in two different cell types.
Discussion
Almost all eukaryote transcription factor classes are currentlymod-
eled as binding to regulatory sites as monomers, homodimers, or
heterodimers. There are a few well-described exceptions to this
rule. The activated heat shock factor (HSF) binds sites as a trimer
(Rabindran et al. 1993). In plants,MADS domain transcription fac-
tors form functional tetramers (Espinosa-Soto et al. 2014). When
signal transducer and activator of transcription (STAT) family
members are activated by JAK-mediated tyrosine phosphorylation,
they form phosphorylated homodimers that translocate to the nu-
cleus and bind GAS motifs (Zhao et al. 2013). Early biochemical
studies showed the formation of STAT tetramers on repeated
motifs with a spacing of 11–12 bp (Vinkemeier et al. 1998).
Recent evidence supporting the conversion of STAT3 from dimers
to tetramers during DNA binding in living cells was presented by
Gaus and colleagues (Hinde et al. 2016), using the pCOMB
technique.
The TP53 tumor-suppressor protein has been extensively
characterized as a tetrameric binding factor (McLure and Lee
1998). The tetrameric protein binds a consensus sequence consist-
ing of two consecutive palindromic half-sites. Tetramerization has
been proposed to result either from an increase in dimer concen-
tration (Bode and Dong 2004) or from a DNA-damage-induced
mechanism (Gaglia et al. 2013). As with the STAT factors, tetrame-
rization of TP53 has been observed by imaging methods in live
cells (Gaglia et al. 2013).
For the large nuclear receptor family, a tetrameric state has
been described for only one member, RXR. The nuclear receptors
contain significant proportions of disorganized structure; thus,
detailed structural information has been available only for the
DBD or LBD portions of the molecules. It is clear, however, that
the unliganded RXR protein can exist as a complete tetramer inde-
pendent of DNAbinding (Kersten et al. 1995; Zhang et al. 2011), in
contrast to the STAT factors and the TP53 protein. Also, in contrast
with STATs and TP53, the tetrameric form of RXR has generally
been considered a repressive form, with ligand dissociation to acti-
vating dimers.
GR oligomeric status has been a matter of continuous debate
(Sacta et al. 2016; Presman and Hager 2017) and is presumed to
be of important pharmacological relevance. This discussion has
centered mostly on the possible involvement of homodimer and
monomer binding (Busillo and Cidlowski 2013; Starick et al.
2015), as well as tethering (Langlais et al. 2012; Ratman et al.
2013) and possible cobinding of monomeric GR with other tran-
scription factors (Cohen and Steger 2017). By using the technique
of number and brightness analysis, we reported that GR adopts a
tetrameric configuration upon binding to a specific GRE in living
cells (Presman et al. 2016). The apparent influence of DNAbinding
on the oligomeric state suggests a parallel with the findings of
an allosteric GR structural transition for the bound receptor
(Meijsing et al. 2009; Watson et al. 2013). By using a mutation
that mimics the DNA-induced allostery (van Tilborg et al. 2000),
we showed the conversion of all activated nuclear receptors to
the tetrameric state (Presman et al. 2016). This observation facili-
tated an examination of the binding and transactivation activity
for this receptor form.
Introduction of the constitutive tetrameric receptor in two
distinct GRKO cells reveals an unprecedented active form of the re-
ceptor. This receptor not only bindsmore robustly to all sites occu-
piedbyGRwtbut also invades a largenumberof sites unavailable to
the wild-type GR (Figs. 1, 5). Chromatin analysis shows that these
newsites are resistant tonuclease digestion and show the lackof ac-
tive histone marks diagnostic of inactive enhancers (Figs. 1, 3, 5).
These features suggest the “tetra-specific” binding sites may be
either tissue-selective enhancers not available in the mammary
knockout cell or random sites unrelated to normal GR function.
A careful examination of overlap between the “tetra-specific”
sites and sites bound by GR in several other cell types supports
the first hypothesis. The vast majority of new sites represent GR
binding elements active in alternate cell types (1198/1808 for
the mammary KO and 868/1517 for the MEF KO) (Figs. 1, 5).
Because almost all tissue types in the body express GR, it is likely
that many of the remaining overlaps correspond to enhancers
active in tissues not represented in the current analysis.
GRtetra is also a more active regulator of gene expression,
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modeled on the basis of tethering, wherein the receptor negatively
modulates the activity of a DNA-bound interacting partner (Glass
and Saijo 2010). Traditional examples include the negative modu-
lation of JUN-FOS (i.e., AP-1) andNFKB1 (also known asNFκB); key
factors in inflammatory responses (Cain and Cidlowski 2017).
Given the strong repressive activity of the GRtetra receptor, we
propose that transrepression as previously defined cannot entirely
explain GR repressive action. In fact, both JUN-FOS and NFKB1
pathways are most likely modulated by GR in a more complex
manner that involves, at least in part, an oligomeric receptor inter-
acting directly with the chromatin landscape (Weikum et al. 2017;
Hudson et al. 2018).
Of the hundreds of thousands of potential binding elements
across the genome, GR only binds a very small subset of sites in a
highly tissue-specific manner (Grbesa and Hakim 2017). The
mechanisms behind GR binding selectivity are likely complex,
but multiple lines of evidence point to chromatin landscape as
a major contributing factor (John et al. 2008, 2011; Love et al.
2017; D’Ippolito et al. 2018; Johnson et al. 2018). A recent study
examined in detail the relationship between nucleosome position,
GR binding potential, and remodeler action (Johnson et al. 2018).
Essentially all binding events involve the action of the SWI/SNF
remodeling complex, either prerecruited by other factors or re-
cruited by the receptor itself. Furthermore, at receptor-dependent
Figure 5. Properties of GRtetra are retained inMEFs. (A) Comparison of endogenous GR inMEFs, reintroduced GRwt, andGRtetra binding in GRKOMEFs
reveals two clusters, C9 (shared by MEF-GRwt and MEF-GRtetra) and C10 (MEF-GRtetra–specific sites). Each heat map represents ±1 kb around the center
of the GR peak. Binding intensity scale is noted below on a linear scale. A two-color binding intensity scale is used for the histone modification data. Heat
maps are sorted based on MEF-GRtetra GFP ChIP-seq binding intensity. (B) Aggregate plots of +Dex GR binding (anti-GFP, or anti-GR for wild-type MEFs)
for each cluster; color indicates cell type with endogenous GR, GRKO, or MEFs expressing GRwt or GRtetra. (C) De novo motif analysis as in Figure 1B. Full
list of enriched de novo motifs is shown in Supplemental Table S2. (D) Aggregate plots of ATAC-seq tag density in untreated MEFs for each GR binding
cluster. (E) Aggregate plots of H3K4me1 ChIP-seq and input tag density in untreated MEFs for each GR binding cluster. (F) Pie chart showing C10 sites
unique or shared with at least one published GR ChIP-seq data set. De novo motif analysis of the most enriched motif shown on the right.
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SMARCA4 recruitment sites, the receptor clearly binds to a pre-
existing nucleosome.
The findings presented herein support the concept of DNA as
an allosteric effector of GR action (Meijsing et al. 2009; Watson
et al. 2013). However, a primary effect ofDNAbinding is to convert
the receptor to a tetrameric state. Whether DNA-induced tetrame-
rization occurs widely or only at a subset of GREs remains an
open question. Nevertheless, the distinct enrichment of GRE mo-
tifs at GRtetra-enhanced sites (C6) may indicate higher oligomeri-
zation states are the general rule rather than the exception.
Integrating both current and previous observations, we suggest a
general model described in Figure 6. The wild-type receptor can
bind both closed nucleosomal and preaccessible sites at active en-
hancers in a given cell type but cannot invade tissue-restricted en-
hancers. When converted constitutively to the tetrameric state via
the P481R mutation, the receptor gains the ability to recruit activ-
ities necessary for activating repressed elements. This “pioneering”
action may simply be a normal activity of the wild-type receptor,
enhanced by the higher concentration, or possibly longer dura-
tion, of the tetrameric state. Further exploration of the dynamic
behavior of the tetrameric receptor in live cells may shed light on
this issue. Itwill alsobe important to examine theactivityof the tet-
rameric form in forming long-range interactions within the nucle-
us, as the tetramer may present a second binding domain able to
interact in trans with distant binding sites (Presman et al. 2016).
In conclusion, we reiterate that the putative oligomeric status
for transcription factors at their binding sites is almost always
inferred from structural studies on purified proteins, deduced
binding motifs, or genomic footprints. The unusual DNA binding
state for GR was discovered using a very specialized form of corre-
lation spectroscopy called number and brightness. It is likely that
many transcription factors originally characterized as monomers
or dimers present higher oligomeric states when evaluated
by these new imaging methods. For example, the progesterone re-
ceptor, considered to be dimeric, forms tetramers in a ligand-
dependent, yet DNA-independent manner (Presman et al. 2016).
These rapid advances in live cell characterization of complex size
and structure at specific binding elements open new opportunities
for understanding the actual status of enhancer activating factors.
Further application of these methods is likely to provide critical
mechanistic insights in this area of gene regulation.
Methods
Cell culture and generation of cell lines by CRISPR/Cas9
All cell lines were grown as previously described (Presman et al.
2016). For details, see Supplemental Methods. To knockout the
stably integrated rat GFP-GR gene and the endogenous Nr3c1
gene, 3617 cells (McNally et al. 2000) were transfected with
pX330 CRISPR/Cas9 plasmid (Addgene 42230) containing guide
RNA sequences to induce random frameshift mutations at those
loci. For further details, see Supplemental Methods. We reintro-
duced the GFP-tagged WT and the mouse GR P481R mutant into
Figure 6. Model of tetrameric GR action on chromatin. Binding of liganded GR to chromatin induces a transition from a dimeric to tetrameric state (1).
GRwt can bind to closed nucleosomal sites (2) and to preaccessible sites (3). At both classes of sites, GRwt can recruit chromatin remodelers and other
cofactors to increase chromatin accessibility and influence gene expression. AP-1 (or other initiating factors) maintains chromatin preaccessible sites before
receptor binding. GRwt is incapable of binding to inaccessible GREs (4). Liganded GRtetra (GR-P481R) is constitutively tetrameric (5). Liganded GRtetra
binds to the same sites as GRwt. The binding of receptor represents transient states (6) with relatively brief residence times in live cells. In addition, GRtetra
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theGT(Rosa)26Sor locus.GFP-integrated cells were selected for sim-
ilar levels of GFP expression and size uniformity.
RNA isolation and RNA-seq data analysis
GRmutant-expressing cells were left untreated or treated with 100
nM of Dex for 2 h before RNA isolation. RNA isolations were per-
formed using the PureLink RNA kit (Thermo Fisher Scientific
12183018A) per themanufacturer’s instructions. RNA-seq libraries
were generated from rRNA-depleted (Illumina RS-122-2301) total-
RNA samples, using Illumina stranded total RNA (Illumina
20020596) according to the manufacturer’s instructions. We se-
quenced at least two biological replicates of each cell line for the
untreated condition and three replicates each for the hormone
treatment condition using an Illumina HiSeq 2500 with pair-end
reads. RNA-seq alignment tomousemm10 genomewas performed
by TopHat2 (2.0.8) (Kim et al. 2013). All RNA-seq biological repli-
cates correlated well with each other (Supplemental Table S4).
Subsequent downstream analysis was performed using HOMER
(Heinz et al. 2010) and DESeq2 (Love et al. 2014).
ChIP-seq and ATAC-seq
GR mutant-expressing cells were left untreated or treated with
100nMofDex (Sigma-Aldrich) for 1 h. ForChIP, after cross-linking
withparaformaldehyde andcell collection, the chromatinwas son-
icated (Bioruptor, Diagenode) to an average DNA length of 200–
500 bp. For immunoprecipitation, 600 µg of chromatin was incu-
bated with antibody (for details, see Supplemental Methods) cou-
pled onto Dynabeads magnetic beads (Thermo Fisher Scientific)
with rotation overnight at 4°C. After stringent washes, the anti-
body-bound chromatin fragments were eluted, the cross-linking
was reversed, and the remaining proteins were digested. DNA was
extracted from the samples with phenol-chloroform extraction
and ethanol precipitation. ChIP-seq libraries were generated using
a TruSeq ChIP sample prep kit (Illumina IP-202-1012) according to
themanufacturer’s instructions. For ATAC, the cells were detached
from the flasks using 5 mL of Accutase (Thermo Fisher Scientific)
by incubating 5 min at RT. After nuclei isolation, ATAC was per-
formed according to the published protocol (Buenrostro et al.
2015). Size selection was performed using SPRIselect (Beckman
Coulter) to remove <150-bp and >800-bp fragments according to
the manufacturer’s instructions. Size selection was verified using
5% TBE PAGE gels (Bio-Rad).
ChIP- and ATAC-seq data analysis
Biological duplicate ChIP samples were sequenced using Illumina
NextSeq 500 with single-end reads, whereas biological duplicate
ATAC samples were sequenced using Illumina HiSeq 4000 with
paired-end reads. The data were aligned to the mouse reference
mm10 genome using Bowtie 2 (Langmead and Salzberg 2012).
All ChIP-seq and ATAC-seq biological replicates correlated
well with each other (Supplemental Table S4). Subsequent
downstream analysis was performed using HOMER (Heinz
et al. 2010). Peaks in each data set were called using findPeaks
with style factor for transcription factors and style histone for
histone modifications. DESeq2 (Love et al. 2014) through
getDiffrentialPeaksReplicates.pl was used to isolate differential
binding peaks (FDR<0.05, FC>3) between the GR mutants.
Data access
Raw data and processed data from this study have been submitted
to the NCBI Gene Expression Omnibus (GEO; https://www.ncbi
.nlm.nih.gov/geo/) under accession number GSE108634.
Accession numbers for all previously published data used in this
study can be found in Supplemental Table S3.
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